Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.

Virchows Archiv : an international journal of pathology·2026

Same author

Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.

Journal of the National Cancer Institute·2026

Same author

Clinical and Molecular Characterization of Clear Cell Adenocarcinoma of the Urinary Tract: A Multi-Institutional Study.

The American journal of surgical pathology·2026

Same author

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Cancer cell·2026

Same author

Comparison of glass-based and whole-slide image-based grade assignment for clear-cell and papillary renal cell carcinoma: a multi-cohort, international reproducibility study.

Histopathology·2025

Same author

Characterization of CD8+ and FOXP3+ T-Cell Ratios in Tumor and Stromal Compartments of Penile Squamous Cell Carcinoma: An Analysis Across Histologic Subtypes and Grades.

International journal of surgical pathology·2025

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Molecular diagnostics in urologic malignancies: a work in progress.

George J Netto¹

¹Department of Pathology, Johns Hopkins Medical Institutions, The Harry and Jeanette Weinberg Building, 401 N Broadway, Baltimore, MD 21231-2410, USA. gnetto1@jhmi.edu

Archives of Pathology & Laboratory Medicine

|April 30, 2011

Summary

This summary is machine-generated.

Urologic oncology lacks molecular diagnostics, unlike other cancers. This review highlights promising biomarkers for improved detection, prognosis, and targeted therapies in urologic malignancies.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Cell-Free DNA Integrity Analysis in Urine Samples

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Related Experiment Videos

Last Updated: Jun 2, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Cell-Free DNA Integrity Analysis in Urine Samples

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Area of Science:

Urologic Oncology
Molecular Diagnostics
Cancer Biomarkers

Background:

Molecular diagnostics are standard in managing breast, colon, and lung cancers.
Urologic oncology clinical management lags in molecular test integration.
There's a need for molecular tests for targeted therapy response and prognostic assessment in urologic cancers.

Purpose of the Study:

To review candidate biomarkers for urologic oncology.
To discuss biomarkers nearing clinical assay transition.

Main Methods:

Literature search of original articles from PubMed.
Focus on biomarkers for urologic malignancies.

Main Results:

Several promising biomarkers are under evaluation for detection, prognosis, and targeted therapeutics.
Understanding molecular alterations in urologic cancers is advancing.

Conclusions:

Novel molecular tools are emerging for diagnosis and prognosis in urologic oncology.
Experimental targeted therapies are becoming feasible for urologic malignancies.